Market Cap
$249.1M
LFCR
LIFECORE BIOMEDICAL, INC. \DE\
$6.54 ▲ +0.15%
Prev close $6.53Market cap$249.1M
ConsensusBuy
12-mo target$6.28 (-4.0%)
▲ Bullish
Analyst conviction 7/10
High Impact Filing (7/10)14 New Institutional Positions4 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on LFCR right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Analyst Consensus
Strong Buy (73%)
Inst. Holders
50 funds
Inst. Value
$43.6M
Inst. Activity
14 buys / 4 sells
Social Sentiment
67° Warm
SEC Reports
4
Press Releases
5
Price chart 30d +50.3%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 29, 2026 other
Aug 5, 2026 SEC $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lifecore Biomedical, Inc. (NASDAQ: LFCR)
NEW YORK, Sept. 29, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Ass
{ "summary": "Lifecore Biomedical reported Q2 2026 revenue of $34.2M (down 6.2% YoY), a GAAP net loss of $6.2M ($0.19
8-K — Impact 5/10
Lifecore Biomedical disclosed that holders of all 49,263 outstanding Series A Redeemable Convertible Preferred shares ha
8-K — Impact 7/10
Jun 30, 2026 Inst.
MARSHALL WACE, LLP — DOUBLED
177,471 shares ($931.7K)
Jun 30, 2026 Inst.
Jun 15, 2026 Press GOLDMAN SACHS GROUP INC — TRIM
124,940 shares ($655.9K)
Lifecore Biomedical announced a new commercial manufacturing agreement with an unnamed global pharmaceutical company for
Impact 6/10
Lifecore Biomedical filed an 8-K reporting the results of its 2026 annual meeting, where stockholders approved the 2026
8-K — Impact 3/10
Jun 4, 2026 Insider
HOUDE LOVAS KATRINA was granted 25,907 shares
Director
Analyst ratings buy % +14.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
73% rate it Buy or better · 11 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 29, 2026 | Barrington Research | DOWNGRADE | Market Perform | 55% |
| Sep 28, 2026 | William Blair | DOWNGRADE | Market Perform | 51% |
| Jun 16, 2026 | Barrington Research | MAINTAIN | Outperform | 55% |
| Apr 29, 2026 | Barrington Research | MAINTAIN | Outperform | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 4 | 4 | 3 | 0 | 0 | 73% | |
| Aug 1, 2026 | 4 | 4 | 3 | 0 | 0 | 73% | |
| Jul 1, 2026 | 4 | 4 | 3 | 0 | 0 | 73% | |
| Jun 1, 2026 | 4 | 4 | 3 | 0 | 0 | 73% | |
| May 1, 2026 | 4 | 4 | 3 | 0 | 0 | 73% | |
| Apr 1, 2026 | 4 | 4 | 3 | 0 | 0 | 73% | |
| Mar 1, 2026 | 3 | 4 | 4 | 0 | 0 | 64% | |
| Feb 1, 2026 | 3 | 4 | 4 | 0 | 0 | 64% |
Price targets
Where 1 covering analysts think LFCR trades over the next 12 months.
$6.28 -4.0% upside Hold
Current$6.54 Low$6.28 Median$6.28 High$6.28 1 analysts
$6.28$6.28
Analyst rating Hold· 3.0/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
67°
Warm
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
4 SEC filing reports analyzed · 0 bullish, 2 bearish, 0 mixed, 2 neutral · avg impact 5.5/10.Plus 5 press releases.
NEUTRAL8-K5/10
{ "summary": "Lifecore Biomedical reported Q2 2026 revenue of $34.2M (down 6.2% YoY), a GAAP net l
Aug 5, 2026
BEARISH8-K7/10
Lifecore Biomedical disclosed that holders of all 49,263 outstanding Series A Redeemable Convertible
Jul 2, 2026
NEUTRAL8-K3/10
Lifecore Biomedical filed an 8-K reporting the results of its 2026 annual meeting, where stockholder
Jun 5, 2026
BEARISH8-K7/10
Lifecore Biomedical reported Q1 2026 revenue of $23.2M, a 34% decline YoY from $35.2M, and a net los
May 6, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 29, 2026
other
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lifecore Biomedical, Inc. (NASDAQ: LFCR)
NEW YORK, Sept. 29, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has reco
Sep 28, 2026
trading_halt
Halt Resumed: LFCR — trading resumed after T3 (News and Resumption Times)
Halted 2026-09-28T12:40:00.000Z | Resumed 2026-09-28T13:50:00.000Z
Sep 28, 2026
m_and_a
Lifecore Biomedical to be Acquired by Webster Equity Partners
Lifecore Biomedical to be Acquired by Webster Equity Partners
Sep 28, 2026
trading_halt
Trading Halt: LFCR — T3 (News and Resumption Times)
Lifecore Biomedical, Inc. Cmn | Market: NASDAQ | Code: T3 — News and Resumption Times
Sep 28, 2026
trading_halt
Trading Halt: LFCR — T1 (News Pending)
Lifecore Biomedical, Inc. Cmn | Market: NASDAQ | Code: T1 — News Pending
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.31 | $-0.33–$-0.30 | — | -4.2% | 0↑ 2↓ | $0.0B | 3 |
| Next Q | $-0.09 | $-0.11–$-0.05 | 45.8% | +13.3% | 1↑ 0↓ | $0.0B | 3 |
| Current FY | $-1.01 | $-1.05–$-0.95 | -86.4% | +0.1% | 1↑ 1↓ | $0.1B | 3 |
| Next FY | $-0.89 | $-1.08–$-0.76 | 11.3% | -1.5% | 2↑ 0↓ | $0.1B | 3 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.310 | — |
| 7d ago | $-0.297 | -0.013 |
| 30d ago | $-0.297 | -0.013 |
| 60d ago | $-0.217 | -0.092 |
| 90d ago | $-0.217 | -0.092 |
Institutional ownership
Which big funds own LFCR (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $43.6M total value (8,302,588 shares) as of 2026-Q2. Top holders: BlackRock,, VANGUARD, GEODE. Net buying activity: 14 institutions added/increased vs 4 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 2,013,093 | $10.6M | 24.3% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,288,621 | $6.8M | 15.5% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 855,500 | $4.5M | 10.3% | — |
| MORGAN STANLEY | 769,360 | $4.0M | 9.3% | — |
| STATE STREET CORP | 668,031 | $3.5M | 8.0% | — |
| NORTHERN TRUST CORP | 253,817 | $1.3M | 3.1% | — |
| VANGUARD FIDUCIARY TRUST CO | 239,924 | $1.3M | 2.9% | — |
| LPL Financial LLC | 207,300 | $1.1M | 2.5% | ADD +84.2% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 189,073 | $992.6K | 2.3% | — |
| MARSHALL WACE, LLP | 177,471 | $931.7K | 2.1% | DOUBLED +204.1% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| MARSHALL WACE, LLP | DOUBLED | 58,354 | 177,471 | +204.1% | $931.7K |
| GOLDMAN SACHS GROUP INC | TRIM | 168,376 | 124,940 | -25.8% | $655.9K |
| Squarepoint Ops LLC | ADD | 52,404 | 92,674 | +76.8% | $486.5K |
| UBS Group AG | ADD | 69,992 | 90,312 | +29.0% | $474.1K |
| Nuveen, LLC | ADD | 35,850 | 52,928 | +47.6% | $277.9K |
| Point72 Asset Management, L.P. | DOUBLED | 25,427 | 52,520 | +106.6% | $275.7K |
| BNP PARIBAS FINANCIAL MARKETS | DOUBLED | 6,770 | 29,855 | +341.0% | $156.7K |
| SIMPLEX TRADING, LLC | DOUBLED | 6,277 | 24,789 | +294.9% | $130.1K |
| WELLS FARGO & COMPANY/MN | DOUBLED | 10,253 | 23,806 | +132.2% | $125.0K |
| CITIGROUP INC | DOUBLED | 2,464 | 13,946 | +466.0% | $73.2K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
10 insiders, 11 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | HOUDE LOVAS KATRINA | Director | AWARD | 25,907 | — | — |
| Jun 4, 2026 | Korenberg Matthew E | Director | AWARD | 25,907 | — | — |
| Jun 4, 2026 | Johnson Paul Harold | Director | AWARD | 25,907 | — | — |
| Jun 4, 2026 | Aryeh Jason | Director | AWARD | 25,907 | — | — |
| Jun 4, 2026 | Antunes Humberto Calheiros | Director | AWARD | 25,907 | — | — |
| Jun 4, 2026 | Schechter Joshua | Director | AWARD | 25,907 | — | — |
| Jun 4, 2026 | OBUS NELSON | Director | AWARD | 25,907 | — | — |
| Jun 4, 2026 | Kiper Christopher S | Director | AWARD | 25,907 | — | — |
| May 20, 2026 | Josephs Paul | Chief Executive Officer | TAX W/H | 40,413 | $4.57 | $184.7K |
| Apr 14, 2026 | Salus Thomas D. | Chief Legal & Administration | TAX W/H | 24,645 | $5.20 | $128.2K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for LFCR.
Shares short
2,669,844
Settlement Sep 15, 2026
Change vs prior
+10.2%
Semi-monthly cycle
Days to cover
15.9
At avg daily volume
Of shares outstanding
≈7.0%
Estimate — not % of float
| Halted | Code | Reason | Status |
|---|---|---|---|
| Sep 28, 2026 | T1 | News Pending | Not resumed |
| Sep 28, 2026 | T2 | News Released | Not resumed |
| Sep 28, 2026 | T3 | Resumption Scheduled | Resumed |
All LFCR filing & press-release reports (9)
- 8-K reportAug 5, 2026
- 8-K reportJul 2, 2026
- PRESS-RELEASE reportJun 15, 2026
- 8-K reportJun 5, 2026
- PRESS-RELEASE reportJun 2, 2026
- 8-K reportMay 6, 2026
- PRESS-RELEASE reportMar 26, 2026
- PRESS-RELEASE reportMar 16, 2026
- PRESS-RELEASE reportMar 4, 2026